These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34111829)

  • 1. A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
    Mustafa M; Abd El-Hafeez AA; Abdelhamid D; Katkar GD; Mostafa YA; Ghosh P; Hayallah AM; Abuo-Rahma GEA
    Eur J Med Chem; 2021 Oct; 222():113569. PubMed ID: 34111829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity.
    Huong TT; Dung DT; Huan NV; Cuong LV; Hai PT; Huong LT; Kim J; Kim YG; Han SB; Nam NH
    Bioorg Chem; 2017 Apr; 71():160-169. PubMed ID: 28196602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents.
    Dung do TM; Dung PT; Oanh DT; Hai PT; Huong le TT; Loi VD; Hahn H; Han BW; Kim J; Han SB; Nam NH
    Med Chem; 2015; 11(8):725-35. PubMed ID: 26133355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
    Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
    Cheng C; Yun F; Ullah S; Yuan Q
    Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
    Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
    Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
    Chen T; Liu Y; Shi M; Tang M; Si W; Yuan X; Wen Y; Chen L
    Bioorg Med Chem Lett; 2021 Dec; 54():128433. PubMed ID: 34757216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
    Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
    Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
    Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
    Lee S; Wang SW; Yu CL; Tai HC; Yen JY; Tuan YL; Wang HH; Liu YT; Chen SS; Lee HY
    Bioorg Med Chem; 2021 Nov; 50():116454. PubMed ID: 34634618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
    Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton.
    Mustafa M; Abuo-Rahma GEA; Abd El-Hafeez AA; Ahmed ER; Abdelhamid D; Ghosh P; Hayallah AM
    Bioorg Med Chem Lett; 2021 May; 40():127965. PubMed ID: 33744442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based optimization of click-based histone deacetylase inhibitors.
    Hou J; Feng C; Li Z; Fang Q; Wang H; Gu G; Shi Y; Liu P; Xu F; Yin Z; Shen J; Wang P
    Eur J Med Chem; 2011 Aug; 46(8):3190-200. PubMed ID: 21621883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Conjugated Quinazolinone-Based Hydroxamic Acids: Design, Synthesis and Biological Evaluation.
    Vu TK; Thanh NT; Minh NV; Linh NH; Thao NTP; Nguyen TTB; Hien DT; Chinh LV; Duc TH; Anh LD; Hai PT
    Med Chem; 2021; 17(7):732-749. PubMed ID: 32310052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
    He R; Chen Y; Chen Y; Ougolkov AV; Zhang JS; Savoy DN; Billadeau DD; Kozikowski AP
    J Med Chem; 2010 Feb; 53(3):1347-56. PubMed ID: 20055418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
    Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
    Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity.
    Zwergel C; Di Bello E; Fioravanti R; Conte M; Nebbioso A; Mazzone R; Brosch G; Mercurio C; Varasi M; Altucci L; Valente S; Mai A
    ChemMedChem; 2021 Mar; 16(6):989-999. PubMed ID: 33220015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.